Cargando…

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders

OBJECTIVE: To evaluate if short‐term treatment with everolimus was safe and could improve neurocognition and behavior in children with TSC. METHODS: This was a prospective, double‐blind randomized, placebo‐controlled two‐center phase II study. Participants diagnosed with TSC and age 6–21 years were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krueger, Darcy A., Sadhwani, Anjali, Byars, Anna W., de Vries, Petrus J., Franz, David N., Whittemore, Vicky H., Filip‐Dhima, Rajna, Murray, Donna, Kapur, Kush, Sahin, Mustafa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740257/ https://www.ncbi.nlm.nih.gov/pubmed/29296616 http://dx.doi.org/10.1002/acn3.494

Ejemplares similares

Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND)
por: de Vries, Petrus J., et al.
Publicado: (2021)

International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)
por: de Vries, Petrus J., et al.
Publicado: (2023)

Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorder
por: Prohl, Anna K., et al.
Publicado: (2019)

The research landscape of tuberous sclerosis complex–associated neuropsychiatric disorders (TAND)—a comprehensive scoping review
por: Vanclooster, Stephanie, et al.
Publicado: (2022)

Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)
por: Alperin, Samuel, et al.
Publicado: (2021)

A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations
por: Hardan, Antonio Y., et al.
Publicado: (2021)

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex
por: Sparagana, Steven, et al.
Publicado: (2017)

A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome
por: Srivastava, Siddharth, et al.
Publicado: (2022)

Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation
por: Hwang, Su-Kyeong, et al.
Publicado: (2016)

Parent-reported measure of repetitive behavior in Phelan-McDermid syndrome
por: Srivastava, Siddharth, et al.
Publicado: (2021)

Reproducibility of Structural and Diffusion Tensor Imaging in the TACERN Multi-Center Study
por: Prohl, Anna K., et al.
Publicado: (2019)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
por: Franz, David N., et al.
Publicado: (2016)

Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex
por: Sánchez Fernández, Iván, et al.
Publicado: (2020)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study
por: Bissler, John J., et al.
Publicado: (2017)

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
por: Krueger, Darcy A., et al.
Publicado: (2013)

The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial
por: Randell, Elizabeth, et al.
Publicado: (2016)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
por: Capal, Jamie K, et al.
Publicado: (2016)

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
por: Franz, David Neal
Publicado: (2013)

Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Everolimus induced organizing pneumonia in a patient with tuberous sclerosis complex
por: Lanfranco, Julio, et al.
Publicado: (2021)

Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex
por: Daccord, Cécile, et al.
Publicado: (2020)

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()
por: Gipson, Tanjala T., et al.
Publicado: (2013)

Erratum: Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019)

Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis
por: Franz, David N., et al.
Publicado: (2015)

Prevalence of thoracoabdominal imaging findings in tuberous sclerosis complex
por: Ritter, David M., et al.
Publicado: (2022)

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2
por: Bissler, John J, et al.
Publicado: (2019)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

The Effect of Everolimus on Subependymal Giant Cell Astrocytoma (SEGA) in Children with Tuberous Sclerosis Complex
por: BAKHTIARY, Hassan, et al.
Publicado: (2021)

Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study
por: Gu, Liangyou, et al.
Publicado: (2021)

Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex
por: Shoji, Tetsuaki, et al.
Publicado: (2021)

Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
por: Luo, Cong, et al.
Publicado: (2021)

Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
por: Moloney, Patrick B., et al.
Publicado: (2021)

Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response
por: Chung, Noelle K X, et al.
Publicado: (2022)

Cardiovascular Manifestations of Tuberous Sclerosis Complex and Summary of the Revised Diagnostic Criteria and Surveillance and Management Recommendations From the International Tuberous Sclerosis Consensus Group
por: Hinton, Robert B., et al.
Publicado: (2014)

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
por: Davies, Mark, et al.
Publicado: (2017)

Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia
por: Leitner, Dominique F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1kd6ld5jkr3g7jsbbrfcnvlv4j